Cantor Fitzgerald Reiterates Overweight Rating for COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, Benzinga reports.

Other research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, March 1st. Morgan Stanley started coverage on COMPASS Pathways in a research report on Monday, April 1st. They set an “overweight” rating and a $30.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $47.40.

COMPASS Pathways Trading Up 0.6 %

Shares of CMPS stock traded up $0.05 during trading hours on Tuesday, hitting $8.16. 34,592 shares of the company were exchanged, compared to its average volume of 675,571. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The firm has a market cap of $505.43 million, a P/E ratio of -3.41 and a beta of 2.48. The company has a 50 day simple moving average of $9.63 and a two-hundred day simple moving average of $8.45. COMPASS Pathways has a fifty-two week low of $5.01 and a fifty-two week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Equities analysts anticipate that COMPASS Pathways will post -2.4 EPS for the current year.

Insider Activity at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Ekaterina Malievskaia sold 25,750 shares of COMPASS Pathways stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $8.65, for a total transaction of $222,737.50. Following the completion of the transaction, the insider now owns 4,036,154 shares of the company’s stock, valued at approximately $34,912,732.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, major shareholder George Jay Goldsmith sold 23,881 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the completion of the transaction, the insider now directly owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Ekaterina Malievskaia sold 25,750 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $8.65, for a total value of $222,737.50. Following the completion of the transaction, the insider now owns 4,036,154 shares in the company, valued at $34,912,732.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,601 shares of company stock worth $1,338,911. 4.25% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. ARK Investment Management LLC increased its stake in COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after acquiring an additional 186,040 shares during the last quarter. Vivo Capital LLC purchased a new position in shares of COMPASS Pathways in the third quarter worth $11,899,000. RA Capital Management L.P. purchased a new stake in COMPASS Pathways during the 3rd quarter valued at $9,516,000. Affinity Asset Advisors LLC bought a new position in shares of COMPASS Pathways during the fourth quarter valued at about $4,812,000. Finally, Laurion Capital Management LP grew its stake in shares of COMPASS Pathways by 169.7% in the third quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock worth $3,781,000 after purchasing an additional 321,500 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.